<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id>
<journal-title>Frontiers in Aging Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Aging Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1663-4365</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnagi.2018.00067</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>ten Kate</surname> <given-names>Mara</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/478717/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Visser</surname> <given-names>Pieter Jelle</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/19933/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bakardjian</surname> <given-names>Hovagim</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barkhof</surname> <given-names>Frederik</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/10249/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Sikkes</surname> <given-names>Sietske A. M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van der Flier</surname> <given-names>Wiesje M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/113088/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Scheltens</surname> <given-names>Philip</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/10248/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Hampel</surname> <given-names>Harald</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff9"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Habert</surname> <given-names>Marie-Odile</given-names></name>
<xref ref-type="aff" rid="aff10"><sup>10</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/155282/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Dubois</surname> <given-names>Bruno</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/21302/overview"/>
</contrib> 
<contrib contrib-type="author">
<name><surname>Tijms</surname> <given-names>Betty M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/83124/overview"/>
</contrib>
<on-behalf-of>INSIGHT-preAD study group</on-behalf-of>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Alzheimer Center &#x00026; Department of Neurology, Amsterdam Neuroscience, VU University Medical Center</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Psychiatry &#x00026; Neuropsychology, School for Mental Health and Neuroscience, Maastricht University</institution>, <addr-line>Maastricht</addr-line>, <country>Netherlands</country></aff>
<aff id="aff3"><sup>3</sup><institution>D&#x000E9;partement de Neurologie, Piti&#x000E9;-Salp&#x000EA;tri&#x000E8;re University Hospital, Institut de la M&#x000E9;moire et de la Maladie d&#x02019;Alzheimer</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff4"><sup>4</sup><institution>Institut du Cerveau et la Moelle Epini&#x000E8;re (ICM)/Brain and Spine Institute, Piti&#x000E9;-Salp&#x000EA;tri&#x000E8;re Hospital, Sorbonne Universities, Pierre and Marie Curie University</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff>
<aff id="aff6"><sup>6</sup><institution>Institutes of Neurology and Healthcare Engineering, University College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff7"><sup>7</sup><institution>Department of Epidemiology and Biostatistics, VU University Medical Center</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff>
<aff id="aff8"><sup>8</sup><institution>AXA Research Fund &#x00026; Sorbonne University Chair</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff9"><sup>9</sup><institution>Sorbonne University, GRC no. 21, Alzheimer Precision Medicine (APM), AP-HP, Piti&#x000E9;-Salp&#x000EA;tri&#x000E8;re Hospital</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff10"><sup>10</sup><institution>Nuclear Medicine Department, Laboratoire d&#x02019;Imagerie Biom&#x000E9;dicale, Sorbonne Universit&#x000E9;s, Piti&#x000E9;-Salp&#x000EA;tri&#x000E8;re University Hospital</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Christian Gaser, Friedrich Schiller Universit&#x000E4;t Jena, Germany</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Panteleimon Giannakopoulos, Universit&#x000E9; de Gen&#x000E8;ve, Switzerland; Yong Liu, Brainnetome Center, China</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: Mara ten Kate <email>m.tenkate1&#x00040;vumc.nl</email></p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>03</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>10</volume>
<elocation-id>67</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>09</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>02</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2018 ten Kate, Visser, Bakardjian, Barkhof, Sikkes, van der Flier, Scheltens, Hampel, Habert, Dubois and Tijms.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>ten Kate, Visser, Bakardjian, Barkhof, Sikkes, van der Flier, Scheltens, Hampel, Habert, Dubois and Tijms</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract><p>The accumulation of amyloid plaques is one of the earliest pathological changes in Alzheimer&#x02019;s disease (AD) and may occur 20 years before the onset of symptoms. Examining associations between amyloid pathology and other early brain changes is critical for understanding the pathophysiological underpinnings of AD. Alterations in gray matter networks might already start at early preclinical stages of AD. In this study, we examined the regional relationship between amyloid aggregation measured with positron emission tomography (PET) and gray matter network measures in elderly subjects with subjective memory complaints. Single-subject gray matter networks were extracted from T1-weigthed structural MRI in cognitively normal subjects (<italic>n</italic> = 318, mean age 76.1 &#x000B1; 3.5, 64% female, 28% amyloid positive). Degree, clustering, path length and small world properties were computed. Global and regional amyloid load was determined using [<sup>18</sup>F]-Florbetapir PET. Associations between standardized uptake value ratio (SUVr) values and network measures were examined using linear regression models. We found that higher global SUVr was associated with lower clustering (<italic>&#x003B2;</italic> = &#x02212;0.12, <italic>p</italic> &#x0003C; 0.05), and small world values (<italic>&#x003B2;</italic> = &#x02212;0.16, <italic>p</italic> &#x0003C; 0.01). Associations were most prominent in orbito- and dorsolateral frontal and parieto-occipital regions. Local SUVr values showed less anatomical variability and did not convey additional information beyond global amyloid burden. In conclusion, we found that in cognitively normal elderly subjects, increased global amyloid pathology is associated with alterations in gray matter networks that are indicative of incipient network breakdown towards AD dementia.</p></abstract>
<kwd-group>
<kwd>amyloid beta</kwd>
<kwd>PET</kwd>
<kwd>gray matter network</kwd>
<kwd>graph theory</kwd>
<kwd>MRI</kwd>
<kwd>subjective memory complaints</kwd>
<kwd>Alzheimer&#x02019;s disease</kwd>
</kwd-group>
<contract-num rid="cn002">ANR-10-AIHU-06</contract-num>
<contract-num rid="cn003">733050506</contract-num>
<contract-sponsor id="cn001">Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale<named-content content-type="fundref-id">10.13039/501100001677</named-content></contract-sponsor>
<contract-sponsor id="cn002">Association Nationale de la Recherche et de la Technologie<named-content content-type="fundref-id">10.13039/501100003032</named-content></contract-sponsor>
<contract-sponsor id="cn003">ZonMw<named-content content-type="fundref-id">10.13039/501100001826</named-content></contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="61"/>
<page-count count="11"/>
<word-count count="8272"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="introduction" id="s1">
<title>Introduction</title>
<p>Amyloid pathology is hypothesized to be one of the earliest events in the pathological cascade of Alzheimer&#x02019;s disease (AD; Jack et al., <xref ref-type="bibr" rid="B20">2013</xref>; Villemagne et al., <xref ref-type="bibr" rid="B53">2013</xref>), and has been associated with future cognitive decline in cognitively normal subjects (Donohue et al., <xref ref-type="bibr" rid="B14">2017</xref>). Understanding associations between amyloid pathology and other early pathological processes is critical as secondary prevention trials are shifting towards the earliest disease stages. AD can be considered as a disconnectivity disease (Delbeuck et al., <xref ref-type="bibr" rid="B13">2003</xref>). In this study, we examined the relation between amyloid depositions measured with positron emission tomography (PET) and disruptions of gray matter networks in elderly subjects.</p>
<p>Brain areas involved in similar cognitive functions tend to develop in a coordinated way (Andrews et al., <xref ref-type="bibr" rid="B4">1997</xref>; Alexander-Bloch et al., <xref ref-type="bibr" rid="B2">2013b</xref>; V&#x000E1;&#x00161;a et al., <xref ref-type="bibr" rid="B51">2018</xref>). Such co-variation of gray matter structure can be measured using structural T1-weighted MRI images and represented as a network (Lerch et al., <xref ref-type="bibr" rid="B27">2006</xref>; Bassett et al., <xref ref-type="bibr" rid="B5">2008</xref>; Tijms et al., <xref ref-type="bibr" rid="B43">2012</xref>; Alexander-Bloch et al., <xref ref-type="bibr" rid="B1">2013a</xref>). In cognitively normal subjects, brain networks tend to have a &#x0201C;small-world&#x0201D; organization, and it has been proposed that such a network organization provides an optimal balance of specialized information processing and integration (Sporns et al., <xref ref-type="bibr" rid="B39">2004</xref>; Humphries and Gurney, <xref ref-type="bibr" rid="B19">2008</xref>; Alexander-Bloch et al., <xref ref-type="bibr" rid="B1">2013a</xref>). Using group level approaches (i.e., one network per diagnostic group), several studies have shown that gray matter network measures are disrupted in AD dementia compared to controls (He et al., <xref ref-type="bibr" rid="B18">2008</xref>; Yao et al., <xref ref-type="bibr" rid="B60">2010</xref>; Pereira et al., <xref ref-type="bibr" rid="B35">2016</xref>). Using our method to extract gray matter networks on a single-subject level (Tijms et al., <xref ref-type="bibr" rid="B43">2012</xref>), we have shown that worse gray matter network disruptions in AD dementia are associated with more severe symptoms, and worse functioning in specific cognitive domains (Tijms et al., <xref ref-type="bibr" rid="B42">2013a</xref>, <xref ref-type="bibr" rid="B47">2014</xref>).</p>
<p>In cognitively normal older adults, lower cerebrospinal fluid (CSF) amyloid beta 1&#x02013;42 levels, indicative of abnormal amyloid aggregation in the brain, already show disrupted gray matter network measures (Tijms et al., <xref ref-type="bibr" rid="B45">2016</xref>), suggesting that at very early stages of the disease networks are starting to disorganize into the direction often observed in dementia stages of AD (Tijms et al., <xref ref-type="bibr" rid="B42">2013a</xref>; Pereira et al., <xref ref-type="bibr" rid="B35">2016</xref>). This suggests that gray matter networks are sensitive to detect very early brain changes related to abnormal amyloid metabolism. However, as CSF is an indirect measure of amyloid plaques it remains unclear whether gray matter network disruptions are linked to local amyloid deposits or to a global effect of amyloid pathology.</p>
<p>In the present study, we examined the regional relationship between amyloid depositions measured with PET and gray matter network disruptions in a large cohort of cognitively normal elderly subjects with subjective memory complaints. Since the Apolipoprotein E (APOE) &#x003B5;4 allele, a genetic risk factor for sporadic AD (Bertram et al., <xref ref-type="bibr" rid="B7">2010</xref>), is associated with amyloid pathology (Jansen et al., <xref ref-type="bibr" rid="B23">2015</xref>) and functional and structural brain changes (Cherbuin et al., <xref ref-type="bibr" rid="B10">2007</xref>; Trachtenberg et al., <xref ref-type="bibr" rid="B48">2012</xref>) in cognitively normal subjects we also examined whether APOE &#x003B5;4 modified the relationship between amyloid and gray matter networks.</p>
</sec>
<sec sec-type="materials and methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Subjects</title>
<p>We analyzed baseline data from the ongoing INSIGHT-preAD study (Dubois et al., <xref ref-type="bibr" rid="B16">2018</xref>). INSIGHT-preAD is a monocentric longitudinal cohort study in 318 cognitively normal elderly (age between 70 and 85 years) with subjective memory complaints recruited from the community in the wider Paris area, France. All subjects underwent amyloid PET and MRI scans as well as an extensive battery of neuropsychological exams. Subjective memory complaints were defined by an affirmative answer to both of the following questions: &#x0201C;are you complaining about your memory&#x0201D;; &#x0201C;is it a regular complaint which lasts more than 6 months?&#x0201D;, in the absence of any objective memory deficits (mini-mental state examination (MMSE) &#x02265; 27, 16-item Free and Cued Selective Reminding Test (FCSRT) total score &#x02265; 41). Exclusion criteria were having a neurological or psychiatric disorder that could interfere with cognition (e.g., epilepsy, brain tumor, stroke), or contra-indication for MRI or amyloid PET scan. APOE genotype was determined as previously described (Teipel et al., <xref ref-type="bibr" rid="B40">2017</xref>). Subjects were classified as APOE &#x003B5;4 carriers if they had one or two APOE &#x003B5;4 alleles and non-carrier otherwise. This study was carried out in accordance with the recommendations of the French national medical research Ethics Committee with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the French national medical research Ethics Committee.</p>
</sec>
<sec id="s2-2">
<title>PET Acquisition and Preprocessing</title>
<p>Amyloid PET images were acquired on a Philips Gemini GXL CT-PET scanner using [<sup>18</sup>F]-Florbetapir (AVID radiopharmaceuticals). Subjects received a single intravenous dose of approximately 370 MBq (range 333&#x02013;407 MBq). Fifty minutes post-injection, three 5-min frames were obtained (128 &#x000D7; 128 acquisition matrix, 2 &#x000D7; 2 &#x000D7; 2 mm<sup>3</sup> voxels). Images were reconstructed using an iterative LOR-RALMA algorithm with 10 iterations and a smooth post-reconstruction filter. Attenuation, scatter and random coincidence corrections were integrated in the reconstruction. Frames were realigned, averaged and quality-checked. Image analysis of PET data was performed by CATI (Centre d&#x02019;acquisition et traitement des images<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref>). Structural MRI images were co-registered to the PET images using Statistical Parametric Mapping software version 8 (SPM8; Wellcome Department of Cognitive Neurology, London, UK). PET images were corrected for partial volume effects with the RBV-sGTM method (Thomas et al., <xref ref-type="bibr" rid="B41">2011</xref>) using gray and white matter tissue maps. Using the normalization parameters from the spatial normalization of structural MRI images, a set of cortical regions of interest (ROIs) was mapped to each subjects&#x02019; native space PET. This was performed for 12 cortical ROIs (bilateral precuneus, posterior and anterior cingulate, inferior parietal, middle temporal gyrus and orbitofrontal cortex) defined in Clark et al. (<xref ref-type="bibr" rid="B11">2012</xref>) and a reference region (a combination of pons and whole cerebellum). For each individual, parametric PET images were created by dividing each voxel by the mean activity extracted from the reference region. Global standardized uptake value ratios (SUVr) were computed by averaging the mean activity of the 12 cortical ROIs. Regional SUVr from the 12 cortical regions was used to explore local relationships between amyloid load and gray matter networks. A global SUVr threshold for abnormality was determined by performing a linear regression analyses between the above-described method and the method used by Besson et al. (<xref ref-type="bibr" rid="B8">2015</xref>) which used PET scans from controls from the IMAP (Multimodal Imaging of Early-Stage AD) study. This strategy has previously been used to reliably estimate relationships between different tracers and processing methods (Landau et al., <xref ref-type="bibr" rid="B26">2014</xref>). A global SUVr threshold of 0.79 corresponded to the IMAP&#x02019;s cohort threshold of 1.005 (Besson et al., <xref ref-type="bibr" rid="B8">2015</xref>). Thus, subjects with a SUVr above 0.79 in the present study were considered amyloid positive.</p>
</sec>
<sec id="s2-3">
<title>MRI Acquisition and Preprocessing</title>
<p>Whole-brain scans were obtained using a 3T scanner (Siemens Magnetom Verio) with a 12-channel head coil. Isotropic structural three-dimensional T1-weighted images were acquired using a sagittal MPRAGE sequence (256 &#x000D7; 240 acquisition matrix, 1 &#x000D7; 1 &#x000D7; 1 mm<sup>3</sup> voxels, repetition time = 2300 ms, echo time = 2.98 ms, inversion time = 900 ms, flip angle = 9&#x000B0;). The structural 3D T1 images were segmented using Statistical Parametric Mapping software version 12 (SPM12; Wellcome Department of Cognitive Neurology, London, UK) running in MATLAB 2011a (MathWorks Inc., Natick, MA, USA). Quality of all gray matter segmentations was visually inspected and none had to be excluded. After segmentation, all gray matter segmentations were resliced into 2 &#x000D7; 2 &#x000D7; 2 mm<sup>3</sup> voxels to reduce the total number of voxels. Total gray matter volume (GMV) and total intracranial volume (TIV; i.e., GMV + white matter volume + CSF) were computed from segmented images in native space.</p>
</sec>
<sec id="s2-4">
<title>Single-Subject Gray Matter Networks</title>
<p>Single-subject gray matter networks were computed based on cortical similarity from native space gray matter segmentations, using an automated method as previously described (Tijms et al., <xref ref-type="bibr" rid="B43">2012</xref><xref ref-type="fn" rid="fn0002"><sup>2</sup></xref>). Briefly, nodes in these networks represent brain areas (regions of 3 &#x000D7; 3 &#x000D7; 3 voxels defined by template free approach as described in Tijms et al. (<xref ref-type="bibr" rid="B43">2012</xref>), and connections are based on similarity in the spatial structure of gray matter density values as quantified with a Pearson&#x02019;s correlation. Networks were binarized using subject-specific thresholds as determined with a random permutation method that ensured a similar chance to include at most 5% spurious correlations in the network (Noble, <xref ref-type="bibr" rid="B31">2009</xref>).</p>
<p>The following network measures were computed based on the average of all nodes: size of the network (i.e., total number of nodes in the network), connectivity density (i.e., ratio of existing connections to maximum possible number of connections), average degree (i.e., number of edges of a node), characteristic path length (i.e., shortest distance between two nodes), clustering coefficient (i.e., level of interconnectedness between the neighbors of a node), and betweenness centrality (i.e., the proportion of characteristic paths that run through a node). Next, we also estimated normalized path length &#x003BB; and normalized clustering coefficient &#x003B3; by dividing the averaged measures across nodes of each network by properties that were derived from averaging 20 randomized reference networks of equal size and degree (Maslov and Sneppen, <xref ref-type="bibr" rid="B28">2002</xref>). Last, we measured the small world network property, which is defined as having more clustering than a random network while having the average path length similar to that of a random network (Watts and Strogatz, <xref ref-type="bibr" rid="B56">1998</xref>). These computations were performed using scripts from the Brain Connectivity Toolbox adapted for large sized networks (Rubinov and Sporns, <xref ref-type="bibr" rid="B37">2010</xref><xref ref-type="fn" rid="fn0003"><sup>3</sup></xref>). For regional network measures, we computed the average network properties across all nodes within each region of the automated anatomical labeling (AAL) atlas (Tzourio-Mazoyer et al., <xref ref-type="bibr" rid="B49">2002</xref>). These 90 anatomical areas were defined for each subject in native space by warping the AAL atlas using the inverted parameters that were calculated when normalizing subject space images to standard space. The 12 cortical regions for which PET data was available were matched to the corresponding AAL region.</p>
</sec>
<sec id="s2-5">
<title>Statistical Analysis</title>
<p>Demographic measures were compared between amyloid positive and amyloid negative subjects using Student&#x02019;s <italic>t</italic>-test or Mann-Whitney-Wilcoxon test for continuous data and chi-square test for categorical data. We used two linear regression models to study the association between global amyloid burden (continuous) and each whole brain network measure. Model 1 included network measure as the dependent variable and age, gender and global amyloid SUVr as independent predictors (model 1). Additional correction for total GMV was performed in model 2. Additionally, we tested whether there was an interaction effect of APOE &#x003B5;4, on the association between amyloid burden and network measures in both models.</p>
<p>For those network measures for which we found a global effect, we examined the regional specificity of amyloid pathology and gray matter network measures using three analyses. In the first analysis, we assessed the association between global amyloid burden and regional network measures. In the second analysis, we examined the association between regional SUVr values and network measures of the same region. In the third analysis, we used the model from the second analysis with additional correction for global SUVr. The aim of this third model was to assess whether regional SUVr values provided additional information above global SUVr. Regional associations were corrected for age, gender, TIV, local GMV and for clustering and path length also local degree. Regional associations were corrected for multiple testing using a false discovery rate (FDR) procedure (<italic>p</italic><sub>FDR</sub>; Benjamini and Yekutieli, <xref ref-type="bibr" rid="B6">2001</xref>). Regional associations were visualized using BrainNet viewer (Xia et al., <xref ref-type="bibr" rid="B58">2013</xref>). All statistical analyses were performed in R (R version 3.3.1<xref ref-type="fn" rid="fn0004"><sup>4</sup></xref>).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Cohort Characteristics</title>
<p>Subject characteristics for the total sample and according to amyloid status are described in Table <xref ref-type="table" rid="T1">1</xref>. We included 318 subjects with a median age of 76 (range 69&#x02013;85) and 204 (64%) were female. All subjects were cognitively normal at the time of inclusion with an average MMSE of 29 (range 27&#x02013;30). All subjects had a fully connected gray matter network with an average size of 6744 nodes (SD = 619) and average network density of 15% (SD = 1). There were 88 (28%) subjects with a positive amyloid PET scan and 58 (18%) of the subjects were APOE &#x003B5;4 carriers. Amyloid positive subjects were older, more often APOE &#x003B5;4 carrier, had lower total GMV, lower clustering and normalized clustering &#x003B3; and lower small world values. Regional amyloid PET SUVr values in the whole sample and according to amyloid status are presented in Supplementary Table S1.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption><p>Clinical characteristics in total sample and according to amyloid status.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Characteristic</th>
<th align="center">Total sample <italic>N</italic> = 318</th>
<th align="center">Amyloid negative <italic>N</italic> = 230</th>
<th align="center">Amyloid positive <italic>N</italic> = 88</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Age years, median (IQR)</td>
<td align="center">76 (74&#x02013;78)</td>
<td align="center">76 (73&#x02013;78)</td>
<td align="center">77 (75&#x02013;79)**</td>
</tr>
<tr>
<td align="left">Female, <italic>N</italic> (%)</td>
<td align="center">204 (64%)</td>
<td align="center">147 (64%)</td>
<td align="center">57 (65%)</td>
</tr>
<tr>
<td align="left">Education, median (IQR)</td>
<td align="center">7 (4&#x02013;8)</td>
<td align="center">7 (5&#x02013;8)</td>
<td align="center">6 (4&#x02013;8)</td>
</tr>
<tr>
<td align="left">MMSE, median (IQR)</td>
<td align="center">29 (28&#x02013;29)</td>
<td align="center">29 (28&#x02013;30)</td>
<td align="center">28 (28&#x02013;29)*</td>
</tr>
<tr>
<td align="left">FCSRT-TR, median (IQR)</td>
<td align="center">47 (45&#x02013;48)</td>
<td align="center">47 (45&#x02013;48)</td>
<td align="center">46 (45&#x02013;48)</td>
</tr>
<tr>
<td align="left">APOE &#x003B5;4 carrier, <italic>N</italic> (%)</td>
<td align="center">58 (18%)</td>
<td align="center">25 (11%)</td>
<td align="center">33 (38%)*</td>
</tr>
<tr>
<td align="left">PET SUVr, median (IQR)</td>
<td align="center">0.71 (0.67&#x02013;0.81)</td>
<td align="center">0.69 (0.65&#x02013;0.73)</td>
<td align="center">0.97 (0.85&#x02013;1.15)**</td>
</tr>
<tr>
<td align="left">Total GMV, mean &#x000B1; SD</td>
<td align="center">0.567 &#x000B1; 0.06</td>
<td align="center">0.571 &#x000B1; 0.06</td>
<td align="center">0.555 &#x000B1; 0.06*</td>
</tr>
<tr>
<td align="left">Network size, mean &#x000B1; SD</td>
<td align="center">6744 &#x000B1; 619</td>
<td align="center">6759 &#x000B1; 629</td>
<td align="center">6703 &#x000B1; 593</td>
</tr>
<tr>
<td align="left">Network degree, mean &#x000B1; SD</td>
<td align="center">1036 &#x000B1; 112</td>
<td align="center">1040 &#x000B1; 114</td>
<td align="center">1026 &#x000B1; 109</td>
</tr>
<tr>
<td align="left">Connectivity density, mean &#x000B1; SD</td>
<td align="center">15 &#x000B1; 0.8</td>
<td align="center">15 &#x000B1; 0.8</td>
<td align="center">15 &#x000B1; 0.8</td>
</tr>
<tr>
<td align="left">Clustering, mean &#x000B1; SD</td>
<td align="center">0.44 &#x000B1; 0.01</td>
<td align="center">0.44 &#x000B1; 0.01</td>
<td align="center">0.43 &#x000B1; 0.01*</td>
</tr>
<tr>
<td align="left">Path length, mean &#x000B1; SD</td>
<td align="center">1.997 &#x000B1; 0.03</td>
<td align="center">1.999 &#x000B1; 0.02</td>
<td align="center">1.995 &#x000B1; 0.03</td>
</tr>
<tr>
<td align="left">Betweenness centrality, mean &#x000B1; SD</td>
<td align="center">6724 &#x000B1; 610</td>
<td align="center">6748 &#x000B1; 626</td>
<td align="center">6662 &#x000B1; 564</td>
</tr>
<tr>
<td align="left">Gamma, mean &#x000B1; SD</td>
<td align="center">1.54 &#x000B1; 0.09</td>
<td align="center">1.55 &#x000B1; 0.08</td>
<td align="center">1.52 &#x000B1; 0.1*</td>
</tr>
<tr>
<td align="left">Lambda, mean &#x000B1; SD</td>
<td align="center">1.08 &#x000B1; 0.01</td>
<td align="center">1.08 &#x000B1; 0.01</td>
<td align="center">1.08 &#x000B1; 0.01</td>
</tr>
<tr>
<td align="left">Small world, mean &#x000B1; SD</td>
<td align="center">1.42 &#x000B1; 0.07</td>
<td align="center">1.43 &#x000B1; 0.06</td>
<td align="center">1.41 &#x000B1; 0.08*</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Key: APOE, apolipoprotein E; FCSRT-TR, total recall of the Free and Cued Selective Reminding Test; GMV, gray matter volume; IQR, interquartile range; MMSE, mini-mental state examination; PET, positron emission tomography; SUVr, standardized uptake value ratio. Cut-point for amyloid positivity SUVr > 0.79. *<italic>p</italic> &#x0003C; 0.05, **<italic>p</italic> &#x0003C; 0.01 different between amyloid positive and amyloid negative subjects</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-2">
<title>Relationship Between Global Amyloid Burden and Whole Brain Network Measures</title>
<p>Higher global amyloid SUVr values were associated with lower total GMV (&#x003B2; = &#x02212;0.1, standard error 0.05, <italic>p</italic> = 0.04). Higher global amyloid SUVr values were associated with whole brain lower clustering, lower normalized clustering coefficient &#x003B3;, lower normalized path length &#x003BB;, and lower small world property when correcting for age and gender (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F1">1</xref>). Normalized clustering coefficient &#x003B3; and small world remained significant after additionally correcting for total GMV. No associations were found between global amyloid SUVr and whole brain network size, degree, network density and betweenness centrality. There was no interaction effect of APOE &#x003B5;4 on the association between global amyloid SUVr and any of the network measures.</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption><p>Associations between global amyloid standardized uptake value ratio (SUVr) and whole brain network measures.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Network property</th>
<th align="center">Model 1 &#x003B2; (standard error)</th>
<th align="center">Model 2 &#x003B2; (standard error)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Gray matter volume</td>
<td align="center">&#x02212;0.1 (0.05)*</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left">Size</td>
<td align="center">&#x02212;0.03 (0.04)</td>
<td align="center">0.04 (0.03)</td>
</tr>
<tr>
<td align="left">Degree</td>
<td align="center">&#x02212;0.03 (0.05)</td>
<td align="center">0.02 (0.04)</td>
</tr>
<tr>
<td align="left">Connectivity density</td>
<td align="center">&#x02212;0.03 (0.06)</td>
<td align="center">&#x02212;0.03 (0.06)</td>
</tr>
<tr>
<td align="left">Clustering</td>
<td align="center">&#x02212;0.12 (0.06)*</td>
<td align="center">&#x02212;0.1 (0.05)</td>
</tr>
<tr>
<td align="left">Path length</td>
<td align="center">&#x02212;0.1 (0.05)</td>
<td align="center">&#x02212;0.06 (0.05)</td>
</tr>
<tr>
<td align="left">Betweenness centrality</td>
<td align="center">&#x02212;0.05 (0.04)</td>
<td align="center">0.02 (0.02)</td>
</tr>
<tr>
<td align="left">Gamma</td>
<td align="center">&#x02212;0.15 (0.05)**</td>
<td align="center">&#x02212;0.09 (0.04)*</td>
</tr>
<tr>
<td align="left">Lambda</td>
<td align="center">&#x02212;0.13 (0.05)*</td>
<td align="center">&#x02212;0.08 (0.05)</td>
</tr>
<tr>
<td align="left">Small world</td>
<td align="center">&#x02212;0.16 (0.05)**</td>
<td align="center">&#x02212;0.09 (0.04)*</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>*p &#x0003C; 0.05, **p &#x0003C; 0.01. Model 1 is adjusted for age and gender. Model 2 is adjusted for age, gender and total gray matter volume. NA, not applicable</italic>.</p>
</table-wrap-foot>
</table-wrap>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Relation between global amyloid standardized uptake value ratio (SUVr) and whole brain network measures. *Indicates significant relationship after correction for age and gender. Gamma and small world remained significant after additional correction for total gray matter volume (GMV). Dotted vertical line represents the cut-off for amyloid positivity (SUVr &#x0003E; 0.79).</p></caption>
<graphic xlink:href="fnagi-10-00067-g0001.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Relationship Between Global Amyloid Burden and Regional Network Measures</title>
<p>Next, we examined the relationship between global amyloid burden and regional network measures to assess whether effects were localized in specific regions or equally distributed across the cortex. Higher global amyloid SUVr values were associated with lower clustering values in right calcarine and left superior occipital gyrus, and with lower path length in the right superior occipital cortex (all <italic>p</italic><sub>FDR</sub> &#x0003C; 0.05). Using a more liberal threshold of an uncorrected <italic>p</italic>-value &#x0003C; 0.05, effects were more widespread including orbito- and dorsolateral frontal and parieto-occipital cortex for clustering, and medial and orbito-frontal, posterior parieto-occipital and temporal regions for path length (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Surface plot of standardized &#x003B2; values of the relationship between global amyloid SUVr and local clustering and path length. Upper row: higher global SUVr was associated with lower clustering values in bilateral superior occipital gyri (left*) and gyrus rectus; left precentral, middle occipital and superior parietal gyri, precuneus, hippocampus and caudate; right superior medial orbito-frontal, inferior parietal, postcentral, supramarginal, and angular gyri, operculum, triangularis, calcarine*, cuneus, paracentral lobule and putamen. Lower row: higher global SUVr was associated with lower path length values in bilateral inferior and orbito-frontal, middle and superior occipital (right*), and lingual gyri, putamen and pallidum; left superior and medial frontal gyri, operculum, supplementary motor area, gyrus rectus, paracentral lobule, caudate, inferior temporal gyrus and middle and superior temporal pole; right precentral, precuneus, inferior occipital, and supramarginal gyri, insula, calcarine and cuneus. Data are presented for regions significant with an uncorrected <italic>p</italic>-value &#x0003C; 0.05. *Indicates region significant at <italic>p</italic><sub>FDR</sub> &#x0003C; 0.05.</p></caption>
<graphic xlink:href="fnagi-10-00067-g0002.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Relationship Between Regional Amyloid Burden and Regional Network Measures</title>
<p>Subsequently we examined the relationship between regional SUVr and network measures of the same region. There were no significant associations at <italic>p</italic><sub>FDR</sub> &#x0003C; 0.05. Repeating the analysis with an exploratory uncorrected <italic>p</italic>-value showed that higher regional amyloid SUVr in the left precuneus was associated with lower clustering in the left precuneus (<italic>&#x003B2;</italic> = &#x02212;0.06, <italic>p</italic> = 0.03), and higher SUVr in the right precuneus was associated with lower path length in the right precuneus (<italic>&#x003B2;</italic> = &#x02212;0.08, <italic>p</italic> = 0.01). We also found an association between higher SUVr in right orbito-frontal cortex and lower path length in right orbito-frontal cortex (<italic>&#x003B2;</italic> = &#x02212;0.06, <italic>p</italic> = 0.03).</p>
<p>Next, we aimed to assess whether changes in network measures were driven by regional amyloid plaques, rather than a global effect of amyloid. However, models in which we additionally corrected for global SUVr suffered from multicollinearity issues, as global SUVr was strongly correlated with regional amyloid burden (all ROIs showed a Pearson&#x02019;s <italic>r</italic> &#x02265; 0.9 with a <italic>p</italic>-value below 1 &#x000D7; 10<sup>&#x02212;20</sup>; Figure <xref ref-type="fig" rid="F3">3B</xref>). This suggests that amyloid was homogenously distributed across the cortex, which was supported by exploratory analysis that show associations of lower clustering in left precuneus with increased PET SUVr values in 10 out of 11 other regions (Figure <xref ref-type="fig" rid="F3">3A</xref>). Similarly, lower path length in right precuneus was also associated with higher amyloid SUVr values in six other regions.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Regional associations of amyloid positron emission tomography (PET) and gray matter network measures.<bold> (A)</bold> Association between regional amyloid PET SUVr (rows) and regional gray matter network measures (columns). Scale indicates &#x003B2; correcting for age, gender, total intracranial volume (TIV) and regional GMV. Only &#x003B2; with a <italic>p</italic> &#x0003C; 0.05 (uncorrected) are displayed. <bold>(B)</bold> Correlation between regional amyloid PET SUVr (rows) and global PET SUVr (column). Scale represents the correlation coefficient. For both <bold>(A,B)</bold>, the size and color of the circle represent the strength of the association. Ant, anterior; clu, clustering; L, left; lgt, path length; Post, posterior; R, right.</p></caption>
<graphic xlink:href="fnagi-10-00067-g0003.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In this study we found that increasing amyloid load measured by amyloid PET is associated with alterations in gray matter network measures in an elderly cohort of cognitively normal subjects with subjective memory complaints. Higher amyloid SUVr was associated with lower clustering, lower normalized clustering &#x003B3;, lower normalized path length &#x003BB;, and lower small world values. Our results suggest that gray matter network alterations may be part of the early pathological changes in AD, which can already be detected in cognitively normal subjects with subjective memory complaints in the absence of manifest cognitive impairment.</p>
<p>Previous studies using group level approaches have found an association between amyloid pathology and gray matter covariance in cognitively normal subjects (Oh et al., <xref ref-type="bibr" rid="B32">2014</xref>; Teipel et al., <xref ref-type="bibr" rid="B40">2017</xref>). Using a multivariate analysis, these studies have found amyloid pathology to be associated with a pattern of decreased GMV in medial temporal lobe, cingulate gyrus and prefrontal cortex. Using a single-subject approach to derive gray matter networks, we extend on these findings by showing within-individual associations between amyloid load and gray matter network changes.</p>
<sec id="s4-1">
<title>Relationship Between Amyloid Burden and Clustering</title>
<p>Results from the present study are in line with our previous study in an independent cohort of cognitively normal subjects, in which we found an association between lower amyloid beta 1&#x02013;42 in CSF (representative of abnormal amyloid metabolism) and changes in gray matter network measures (Tijms et al., <xref ref-type="bibr" rid="B45">2016</xref>). In that study we also found an association between increased amyloid pathology and whole brain lower clustering values, indicating that there are fewer connections between neighboring areas in the brain, suggesting less effective local integration. Here, using PET to measure amyloid depositions in the brain we extend those findings by showing that lower <italic>normalized</italic> clustering values &#x003B3; are also associated with more severe amyloid burden. Changes in normalized clustering values &#x003B3; suggest that the global network organization is also affected by amyloid deposition. In our previous study we did not find an association between normalized clustering and amyloid CSF (Tijms et al., <xref ref-type="bibr" rid="B45">2016</xref>). A potential explanation for this discrepancy could be the difference in age between both populations, as subjects in the current study are approximately 20 years older than in our previous CSF study (median age 56 vs. 76 years). As amyloid pathology increases with age, subjects in the present study had on average more amyloid pathology (28% being classified as amyloid abnormal vs. 6% in the previous study). The percentage amyloid positive subjects falls within the expected range for the age group in both studies (Jansen et al., <xref ref-type="bibr" rid="B23">2015</xref>). Another explanation for the differences in findings could be the method to measure amyloid pathology. Some studies have suggested that amyloid alterations may be detected somewhat earlier in CSF than on PET (Mattsson et al., <xref ref-type="bibr" rid="B30">2015</xref>; Palmqvist et al., <xref ref-type="bibr" rid="B34">2016</xref>), which is particularly relevant in cognitively normal subjects. CSF and PET measure slightly different aspects of amyloid pathology. In CSF, soluble amyloid beta 1&#x02013;42 monomeres are measured, which decrease when amyloid aggregates in the brain. Soluble CSF amyloid beta 1&#x02013;42 levels may also be influenced by other factors such as amyloid beta production and non-fibrillary aggregation (Mattsson et al., <xref ref-type="bibr" rid="B30">2015</xref>), possibly making CSF more sensitive for the earliest stages of amyloid aggregation. Amyloid PET provides a more direct measure of amyloid deposition with ligands binding to the amyloid beta in fibrillary plaques (Mathis et al., <xref ref-type="bibr" rid="B29">2012</xref>), leading to floor effects within the normal range. It is likely that in our previous study in a younger population that showed mostly normal CSF values, we captured the earliest signs of incipient network disorganization related to very early pathological changes. Lower clustering values associated with increased amyloid load have also been observed for structural connectivity measured with diffusion tensor imaging, independent of cognitive status (Prescott et al., <xref ref-type="bibr" rid="B36">2014</xref>). Lower gray matter clustering values have previously also been reported in subjects with AD dementia and subjects with mild cognitive impairment who later convert to dementia (Tijms et al., <xref ref-type="bibr" rid="B42">2013a</xref>, <xref ref-type="bibr" rid="B44">2018</xref>; Pereira et al., <xref ref-type="bibr" rid="B35">2016</xref>). Taking together, these studies might suggest that during the progression of Alzheimer pathology, clustering values gradually worsen starting with decreased regional connections, and progressively leading to more extensive changes rendering networks more similar to randomly organized networks.</p>
</sec>
<sec id="s4-2">
<title>Relationship Between Amyloid Burden and Path Length</title>
<p>The relationship between amyloid pathology and path length is less straightforward. In this study we found an association between increased amyloid pathology on PET and lower normalized path length &#x003BB; values, although not significant when correcting for GMV. In our earlier CSF study, we found an opposite association with lower CSF values being associated with increased un-normalized path length (Tijms et al., <xref ref-type="bibr" rid="B45">2016</xref>). In that study, the increased path length values were accompanied by lower connectivity density values. With decreasing number of connections, the average path length may increase. In the present study, we did not find an association between amyloid pathology and connectivity density. Possibly, this discrepancy is explained by the age-difference between the populations studied. Network density may decrease with advancing age, and the average connectivity density was 15% in the present study, compared to 20% in our previous younger cohort. Path length values might also change non-linearly during the progression of Alzheimer pathology. Possibly, path length values first increase in the earliest stages of amyloid accumulation due to the loss of connections, and eventually decrease again when the network breaks down and becomes more randomly organized. Such an inverted U-shape trajectory of path length changes has previously been observed in functional networks during aging (Smit et al., <xref ref-type="bibr" rid="B38">2012</xref>). Decreased path length values associated with network breakdown might reflect advanced disease stages when many brain areas show atrophy, and thus would show spurious similarities. In patients with AD dementia, both decreased and increased path length values have been reported across and within different imaging modalities (Xie and He, <xref ref-type="bibr" rid="B59">2012</xref>; Tijms et al., <xref ref-type="bibr" rid="B46">2013b</xref>; Kim et al., <xref ref-type="bibr" rid="B25">2016</xref>; Duan et al., <xref ref-type="bibr" rid="B15">2017</xref>). Given these inconsistencies in literature regarding path length changes in AD, and the influence of other variables on path length, path length may not be a good measure to assess and track AD-related gray matter connectivity changes. Longitudinal studies are needed to further characterize normal gray matter network changes associated with aging and pathological changes associated with amyloid pathology and brain atrophy.</p>
</sec>
<sec id="s4-3">
<title>Relationship Between Amyloid Burden and Small World Values</title>
<p>Finally, we found an association between increased amyloid SUVr and lower small world values. Small world values indicate how much a network is locally integrated compared to a random network while remaining short path length. Small world values are based on the relation between normalized clustering coefficient and normalized path length. Hence, changes in small world values can be caused by a change in either of these measures. In this study, the decrease in small world values associated with increasing amyloid load can be explained by a relatively higher decrease in normalized clustering compared to normalized path length with increasing amyloid load. Decreases in small world values have previously also been reported in subjects with AD dementia compared to cognitively normal subjects (Tijms et al., <xref ref-type="bibr" rid="B42">2013a</xref>; Kim et al., <xref ref-type="bibr" rid="B25">2016</xref>; Pereira et al., <xref ref-type="bibr" rid="B35">2016</xref>), and have been associated with future cognitive decline in amyloid positive non-demented subjects (Tijms et al., <xref ref-type="bibr" rid="B44">2018</xref>). Some studies have also reported increased small-world values in subjects with AD dementia for different imaging modalities (Tijms et al., <xref ref-type="bibr" rid="B46">2013b</xref>; Duan et al., <xref ref-type="bibr" rid="B15">2017</xref>). Differences between studies might be due to differences in methods to construct the networks or non-linear changes with disease progression, possibly reflecting non-linear changes in path length. Longitudinal studies are needed to further investigate trajectories of network changes with advancing disease.</p>
</sec>
<sec id="s4-4">
<title>Regional Associations Between Amyloid PET and Gray Matter Network Measures</title>
<p>At a local level, increased global amyloid PET SUVr values were associated with decreased clustering in orbito- and dorsolateral frontal areas as well as parieto-occipital areas. Several of the regional correlations correspond to our previous results with CSF amyloid values (Tijms et al., <xref ref-type="bibr" rid="B45">2016</xref>). Increased global amyloid PET was also associated with decreased path length in various brain areas. The associations between global amyloid and regional changes were quite widespread, and some of these areas are known regions of amyloid depositions (Braak and Braak, <xref ref-type="bibr" rid="B9">1996</xref>). When examining the relationship between regional amyloid load and regional network changes, we found an effect in the precuneus and orbito-frontal cortex. These may be the regions of earliest amyloid accumulation (Villeneuve et al., <xref ref-type="bibr" rid="B55">2015</xref>). When we further studied the anatomical specificity of these relationships, however, we found that much of the observed associations between local network measures and amyloid pathology were largely explained by global amyloid SUVr values. Our results are in line with other studies that did not find a direct relationship between local amyloid plaque deposits and localized measures of neuronal injury (Jack et al., <xref ref-type="bibr" rid="B21">2008</xref>; Altmann et al., <xref ref-type="bibr" rid="B3">2015</xref>; Grothe and Teipel, <xref ref-type="bibr" rid="B17">2016</xref>). Possibly, the poor anatomical correspondence between localized plaque burden and neuronal injury markers is explained by the delay in time that these biomarkers become abnormal. Amyloid pathology may start to accumulate up to 20 years before the onset of symptoms and plateaus at a relatively early stage (Jack et al., <xref ref-type="bibr" rid="B20">2013</xref>; Villemagne et al., <xref ref-type="bibr" rid="B53">2013</xref>). Markers of neurodegeneration on the other hand, are more closely related to the onset of symptoms (Jack et al., <xref ref-type="bibr" rid="B22">2009</xref>; Da et al., <xref ref-type="bibr" rid="B12">2014</xref>). Gray matter network alterations might be sensitive to detect very subtle brain structural changes associated with amyloid pathology, and precede more overt manifestations of neurodegeneration such as atrophy. Longitudinal studies are necessary to further examine the temporal relation between amyloid deposits and gray matter network changes. Possibly, the observed association between amyloid and gray matter network measures may reflect the presence of tau in addition to amyloid pathology. Regional tau deposits may show more clear associations with regional disruptions of brain structure and function (Ossenkoppele et al., <xref ref-type="bibr" rid="B70">2016</xref>; Xia et al., <xref ref-type="bibr" rid="B57">2017</xref>). With the advent of new tau-binding ligands for PET, the anatomical relation between amyloid plaques, tau deposits and gray matter network changes can be examined in future studies (Villemagne et al., <xref ref-type="bibr" rid="B54">2015</xref>).</p>
</sec>
<sec id="s4-5">
<title>Effect of APOE</title>
<p>In agreement with previous studies in cognitively normal subjects, we did not find an effect of APOE &#x003B5;4 genotype, a major genetic risk factor for AD, on the association between amyloid pathology and gray matter network measures (Oh et al., <xref ref-type="bibr" rid="B33">2011</xref>; Tijms et al., <xref ref-type="bibr" rid="B45">2016</xref>; Teipel et al., <xref ref-type="bibr" rid="B40">2017</xref>). Although APOE &#x003B5;4 genotype has been associated with amyloid pathology in cognitively normal subjects in a large meta-analysis study (Jansen et al., <xref ref-type="bibr" rid="B23">2015</xref>), it seems that subsequent structural brain alterations are not different for APOE &#x003B5;4 carriers and non-carriers. This suggests that APOE &#x003B5;4 most strongly affects (the age of) amyloid aggregation, but not necessarily the anatomical locations that will show most pronounced structural brain changes.</p>
</sec>
<sec id="s4-6">
<title>Limitations</title>
<p>A potential limitation of the present study is that we only had local SUVr values available for a subset of anatomically relevant cortical regions, for which the regional SUVr were all highly correlated with global SUVr. As such, the possibility that other anatomical areas might show more variability in amyloid depositions cannot be excluded (Villain et al., <xref ref-type="bibr" rid="B52">2012</xref>). Additionally, amyloid load was assessed using semiquantitative SUVr values, which do not take into account confounding variables that may influence tracer uptake, such as flow effects, and so this might have introduced noise to the data (van Berckel et al., <xref ref-type="bibr" rid="B50">2013</xref>). We presently studied subjects with subjective memory complaints, a population that might be enriched for preclinical AD, because these subjects may have higher chances of amyloid pathology and be at increased risk of cognitive decline (Jessen et al., <xref ref-type="bibr" rid="B24">2014</xref>). Although this makes our study clinically relevant, this limits generalizability to the broader population. We used a cross-sectional approach to study the relationship between amyloid PET and gray matter networks. Longitudinal amyloid PET and structural MRI data might give more insight into the relationship between amyloid pathology, gray matter network disruptions and cognitive decline. Finally, it is possible that the association between amyloid and gray matter network changes reflects the presence of tau pathology. We were not able to examine this in the present sample as we did not have information on tau pathology from CSF or PET. Future studies may focus on examining the relationship between amyloid, tau and gray matter network changes.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>In summary, we found that in cognitively normal subjects, global amyloid burden is associated with alterations in gray matter network measures. These results suggest that gray matter network alterations may occur at a very early stage in the pathogenesis of AD.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>MK and BMT analyzed the data and drafted the manuscript. PJV, HB, FB, SAMS, WMF, PS, HH, M-OH and BD revised the manuscript for important intellectual content. HB, HH, BD and BMT conceived and designed the study.</p>
</sec>
<sec id="s7">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>INSIGHT-preAD study group: Audrain C, Auffret A, Bakardjian H, Baldacci F, Batrancourt B, Benakki I, Benali H, Bertin H, Bertrand A, Boukadida L, Cacciamani F, Causse V, Cavedo E, Cherif Touil S, Chiesa PA, Colliot O, Dalla Barba G, Depaulis M, Dos Santos A, Dubois B, Dubois M, Epelbaum S, Fontaine B, Francisque H, Gagliardi G, Genin A, Genthon R, Glasman P, Gombert F, Habert MO, Hampel H, Hewa H, Houot M, Jungalee N, Kas A, Kilani M, La Corte V, Le Roy F, Lehericy S, Letondor C, Levy M, Lista S, Lowrey M, Ly J, Makiese O, Masetti I, Mendes A, Metzinger C, Michon A, Mochel F, Nait Arab R, Nyasse F, Perrin C, Poirier F, Poisson C, Potier MC, Ratovohery S, Revillon M, Rojkova K, Santos-Andrade K, Schindler R, Servera MC, Seux L, Simon V, Skovronsky D, Thiebaut M, Uspenskaya O, Vlaincu M. INSIGHT-preAD Scientific Committee Members: Dubois B, Hampel H, Bakardjian H, Colliot O, Habert MO, Lamari F, Mochel F, Potier MC, Thiebaut de Schotten M.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> The study was promoted by Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale (INSERM) in collaboration with ICM, IHU-A-ICM and Pfizer and has received support within the &#x0201C;Investissement d&#x02019;Avenir&#x0201D; (Association Nationale de la Recherche et de la Technologie (ANR)-10-AIHU-06) program. The study was promoted in collaboration with the &#x0201C;CHU de Bordeaux&#x0201D; (coordination CIC EC7), the promoter of Memento cohort, funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/Lilly. This research publication benefited from the support of the Program &#x0201C;PHOENIX&#x0201D; led by the Sorbonne University Foundation and sponsored by la Fondation pour la Recherche sur Alzheimer. MK and PJV are appointed on a grant from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF Grant No. 115372). HH is supported by the AXA Research Fund, the &#x0201C;Fondation partenariale Sorbonne Universit&#x000E9;&#x0201D; and the &#x0201C;Fondation pour la Recherche sur Alzheimer&#x0201D;, Paris, France. Ce travail a b&#x000E9;n&#x000E9;fici&#x000E9; d&#x02019;une aide de l&#x02019;Etat &#x0201C;Investissements d&#x02019;avenir&#x0201D; ANR-10-IAIHU-06. BMT received funding from the Memorabel grant programme of the Netherlands Organisation for Health Research and Development (ZonMW Grant No. 733050506). FB is supported by the NIHR biomedical research center at UCLH.</p>
</fn>
</fn-group>
<sec sec-type="supplementary material" id="s8">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fnagi.2018.00067/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fnagi.2018.00067/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.PDF" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexander-Bloch</surname> <given-names>A.</given-names></name> <name><surname>Giedd</surname> <given-names>J. N.</given-names></name> <name><surname>Bullmore</surname> <given-names>E.</given-names></name></person-group> (<year>2013a</year>). <article-title>Imaging structural co-variance between human brain regions</article-title>. <source>Nat. Rev. Neurosci.</source> <volume>14</volume>, <fpage>322</fpage>&#x02013;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3465</pub-id><pub-id pub-id-type="pmid">23531697</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexander-Bloch</surname> <given-names>A.</given-names></name> <name><surname>Raznahan</surname> <given-names>A.</given-names></name> <name><surname>Bullmore</surname> <given-names>E.</given-names></name> <name><surname>Giedd</surname> <given-names>J.</given-names></name></person-group> (<year>2013b</year>). <article-title>The convergence of maturational change and structural covariance in human cortical networks</article-title>. <source>J. Neurosci.</source> <volume>33</volume>, <fpage>2889</fpage>&#x02013;<lpage>2899</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3554-12.2013</pub-id><pub-id pub-id-type="pmid">23407947</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altmann</surname> <given-names>A.</given-names></name> <name><surname>Ng</surname> <given-names>B.</given-names></name> <name><surname>Landau</surname> <given-names>S. M.</given-names></name> <name><surname>Jagust</surname> <given-names>W. J.</given-names></name> <name><surname>Greicius</surname> <given-names>M. D.</given-names></name> <collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab></person-group>. (<year>2015</year>). <article-title>Regional brain hypometabolism is unrelated to regional amyloid plaque burden</article-title>. <source>Brain</source> <volume>138</volume>, <fpage>3734</fpage>&#x02013;<lpage>3746</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awv278</pub-id><pub-id pub-id-type="pmid">26419799</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname> <given-names>T. J.</given-names></name> <name><surname>Halpern</surname> <given-names>S. D.</given-names></name> <name><surname>Purves</surname> <given-names>D.</given-names></name></person-group> (<year>1997</year>). <article-title>Correlated size variations in human visual cortex, lateral geniculate nucleus, and optic tract</article-title>. <source>J. Neurosci.</source> <volume>17</volume>, <fpage>2859</fpage>&#x02013;<lpage>2868</lpage>. <pub-id pub-id-type="pmid">9092607</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bassett</surname> <given-names>D. S.</given-names></name> <name><surname>Bullmore</surname> <given-names>E.</given-names></name> <name><surname>Verchinski</surname> <given-names>B. A.</given-names></name> <name><surname>Mattay</surname> <given-names>V. S.</given-names></name> <name><surname>Weinberger</surname> <given-names>D. R.</given-names></name> <name><surname>Meyer-Lindenberg</surname> <given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Hierarchical organization of human cortical networks in health and schizophrenia</article-title>. <source>J. Neurosci.</source> <volume>28</volume>, <fpage>9239</fpage>&#x02013;<lpage>9248</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1929-08.2008</pub-id><pub-id pub-id-type="pmid">18784304</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname> <given-names>Y.</given-names></name> <name><surname>Yekutieli</surname> <given-names>D.</given-names></name></person-group> (<year>2001</year>). <article-title>The control of the false discovery rate in multiple testing under dependency</article-title>. <source>Ann. Stat.</source> <volume>29</volume>, <fpage>1165</fpage>&#x02013;<lpage>1188</lpage>. <pub-id pub-id-type="doi">10.1214/aos/1013699998</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname> <given-names>L.</given-names></name> <name><surname>Lill</surname> <given-names>C. M.</given-names></name> <name><surname>Tanzi</surname> <given-names>R. E.</given-names></name></person-group> (<year>2010</year>). <article-title>The genetics of alzheimer disease: back to the future</article-title>. <source>Neuron</source> <volume>68</volume>, <fpage>270</fpage>&#x02013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.10.013</pub-id><pub-id pub-id-type="pmid">20955934</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Besson</surname> <given-names>F. L.</given-names></name> <name><surname>La Joie</surname> <given-names>R.</given-names></name> <name><surname>Doeuvre</surname> <given-names>L.</given-names></name> <name><surname>Gaubert</surname> <given-names>M.</given-names></name> <name><surname>M&#x000E9;zenge</surname> <given-names>F.</given-names></name> <name><surname>Egret</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer&#x02019;s disease</article-title>. <source>J. Neurosci.</source> <volume>35</volume>, <fpage>10402</fpage>&#x02013;<lpage>10411</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0150-15.2015</pub-id><pub-id pub-id-type="pmid">26203136</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname> <given-names>H.</given-names></name> <name><surname>Braak</surname> <given-names>E.</given-names></name></person-group> (<year>1996</year>). <article-title>Evolution of the neuropathology of Alzheimer&#x02019;s disease</article-title>. <source>Acta Neurol. Scand.</source> <volume>94</volume>, <fpage>3</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0404.1996.tb05866.x</pub-id><pub-id pub-id-type="pmid">8740983</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cherbuin</surname> <given-names>N.</given-names></name> <name><surname>Leach</surname> <given-names>L. S.</given-names></name> <name><surname>Christensen</surname> <given-names>H.</given-names></name> <name><surname>Anstey</surname> <given-names>K. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Neuroimaging and <italic>APOE</italic> genotype: a systematic qualitative review</article-title>. <source>Dement. Geriatr. Cogn. Disord.</source> <volume>24</volume>, <fpage>348</fpage>&#x02013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1159/000109150</pub-id><pub-id pub-id-type="pmid">17911980</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>C. M.</given-names></name> <name><surname>Pontecorvo</surname> <given-names>M. J.</given-names></name> <name><surname>Beach</surname> <given-names>T. G.</given-names></name> <name><surname>Bedell</surname> <given-names>B. J.</given-names></name> <name><surname>Coleman</surname> <given-names>R. E.</given-names></name> <name><surname>Doraiswamy</surname> <given-names>P. M.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x003B2; plaques: a prospective cohort study</article-title>. <source>Lancet Neurol.</source> <volume>11</volume>, <fpage>669</fpage>&#x02013;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1016/s1474-4422(12)70142-4</pub-id><pub-id pub-id-type="pmid">22749065</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Da</surname> <given-names>X.</given-names></name> <name><surname>Toledo</surname> <given-names>J. B.</given-names></name> <name><surname>Zee</surname> <given-names>J.</given-names></name> <name><surname>Wolk</surname> <given-names>D. A.</given-names></name> <name><surname>Xie</surname> <given-names>S. X.</given-names></name> <name><surname>Ou</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers</article-title>. <source>Neuroimage Clin.</source> <volume>4</volume>, <fpage>164</fpage>&#x02013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1016/j.nicl.2013.11.010</pub-id><pub-id pub-id-type="pmid">24371799</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delbeuck</surname> <given-names>X.</given-names></name> <name><surname>Van der Linden</surname> <given-names>M.</given-names></name> <name><surname>Collette</surname> <given-names>F.</given-names></name></person-group> (<year>2003</year>). <article-title>Alzheimer&#x02019;s disease as a disconnection syndrome?</article-title> <source>Neuropsychol. Rev.</source> <volume>13</volume>, <fpage>79</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1023/A:1023832305702</pub-id><pub-id pub-id-type="pmid">12887040</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname> <given-names>M. C.</given-names></name> <name><surname>Sperling</surname> <given-names>R. A.</given-names></name> <name><surname>Petersen</surname> <given-names>R.</given-names></name> <name><surname>Sun</surname> <given-names>C.-K.</given-names></name> <name><surname>Weiner</surname> <given-names>M. W.</given-names></name> <name><surname>Aisen</surname> <given-names>P. S.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons</article-title>. <source>JAMA</source> <volume>317</volume>, <fpage>2305</fpage>&#x02013;<lpage>2316</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.6669</pub-id><pub-id pub-id-type="pmid">28609533</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>H.</given-names></name> <name><surname>Jiang</surname> <given-names>J.</given-names></name> <name><surname>Xu</surname> <given-names>J.</given-names></name> <name><surname>Zhou</surname> <given-names>H.</given-names></name> <name><surname>Huang</surname> <given-names>Z.</given-names></name> <name><surname>Yu</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Differences in A&#x003B2; brain networks in Alzheimer&#x02019;s disease and healthy controls</article-title>. <source>Brain Res.</source> <volume>1655</volume>, <fpage>77</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2016.11.019</pub-id><pub-id pub-id-type="pmid">27867033</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname> <given-names>B.</given-names></name> <name><surname>Epelbaum</surname> <given-names>S.</given-names></name> <name><surname>Nyasse</surname> <given-names>F.</given-names></name> <name><surname>Bakardjian</surname> <given-names>H.</given-names></name> <name><surname>Gagliardi</surname> <given-names>G.</given-names></name> <name><surname>Uspenskaya</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Cognitive and neuroimaging parameters and brain amyloidosis in individuals with Alzheimer&#x02019;s disease (INSIGHT-preAD): a longitudinal observational study</article-title>. <source>Lancet Neurol.</source> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/s1474-4422(18)30029-2</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grothe</surname> <given-names>M. J.</given-names></name> <name><surname>Teipel</surname> <given-names>S. J.</given-names></name> <collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab></person-group>. (<year>2016</year>). <article-title>Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer&#x02019;s disease correspond to dissociable functional brain networks</article-title>. <source>Hum. Brain Mapp.</source> <volume>37</volume>, <fpage>35</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.23018</pub-id><pub-id pub-id-type="pmid">26441321</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>Z.</given-names></name> <name><surname>Evans</surname> <given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Structural insights into aberrant topological patterns of large-scale cortical networks in Alzheimer&#x02019;s disease</article-title>. <source>J. Neurosci.</source> <volume>28</volume>, <fpage>4756</fpage>&#x02013;<lpage>4766</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0141-08.2008</pub-id><pub-id pub-id-type="pmid">18448652</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname> <given-names>M. D.</given-names></name> <name><surname>Gurney</surname> <given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Network &#x02018;small-world-ness&#x02019;: a quantitative method for determining canonical network equivalence</article-title>. <source>PLoS One</source> <volume>3</volume>:<fpage>e0002051</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0002051</pub-id><pub-id pub-id-type="pmid">18446219</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname> <given-names>C. R.</given-names> <suffix>Jr.</suffix></name> <name><surname>Knopman</surname> <given-names>D. S.</given-names></name> <name><surname>Jagust</surname> <given-names>W. J.</given-names></name> <name><surname>Petersen</surname> <given-names>R. C.</given-names></name> <name><surname>Weiner</surname> <given-names>M. W.</given-names></name> <name><surname>Aisen</surname> <given-names>P. S.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Tracking pathophysiological processes in Alzheimer&#x02019;s disease: an updated hypothetical model of dynamic biomarkers</article-title>. <source>Lancet Neurol.</source> <volume>12</volume>, <fpage>207</fpage>&#x02013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(12)70291-0</pub-id><pub-id pub-id-type="pmid">23332364</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname> <given-names>C. R.</given-names> <suffix>Jr.</suffix></name> <name><surname>Lowe</surname> <given-names>V. J.</given-names></name> <name><surname>Senjem</surname> <given-names>M. L.</given-names></name> <name><surname>Weigand</surname> <given-names>S. D.</given-names></name> <name><surname>Kemp</surname> <given-names>B. J.</given-names></name> <name><surname>Shiung</surname> <given-names>M. M.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x02019;s disease and amnestic mild cognitive impairment</article-title>. <source>Brain</source> <volume>131</volume>, <fpage>665</fpage>&#x02013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awm336</pub-id><pub-id pub-id-type="pmid">18263627</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname> <given-names>C. R.</given-names> <suffix>Jr.</suffix></name> <name><surname>Lowe</surname> <given-names>V. J.</given-names></name> <name><surname>Weigand</surname> <given-names>S. D.</given-names></name> <name><surname>Wiste</surname> <given-names>H. J.</given-names></name> <name><surname>Senjem</surname> <given-names>M. L.</given-names></name> <name><surname>Knopman</surname> <given-names>D. S.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x02019;s disease: implications for sequence of pathological events in Alzheimer&#x02019;s disease</article-title>. <source>Brain</source> <volume>132</volume>, <fpage>1355</fpage>&#x02013;<lpage>1365</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awp062</pub-id><pub-id pub-id-type="pmid">19339253</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname> <given-names>W. J.</given-names></name> <name><surname>Ossenkoppele</surname> <given-names>R.</given-names></name> <name><surname>Knol</surname> <given-names>D. L.</given-names></name> <name><surname>Tijms</surname> <given-names>B. M.</given-names></name> <name><surname>Scheltens</surname> <given-names>P.</given-names></name> <name><surname>Verhey</surname> <given-names>F. R. J.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis</article-title>. <source>JAMA</source> <volume>313</volume>, <fpage>1924</fpage>&#x02013;<lpage>1938</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2015.4668</pub-id><pub-id pub-id-type="pmid">25988462</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jessen</surname> <given-names>F.</given-names></name> <name><surname>Amariglio</surname> <given-names>R. E.</given-names></name> <name><surname>van Boxtel</surname> <given-names>M.</given-names></name> <name><surname>Breteler</surname> <given-names>M.</given-names></name> <name><surname>Ceccaldi</surname> <given-names>M.</given-names></name> <name><surname>Ch&#x000E9;telat</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement.</source> <volume>10</volume>, <fpage>844</fpage>&#x02013;<lpage>852</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2014.01.001</pub-id><pub-id pub-id-type="pmid">24798886</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>H.-J.</given-names></name> <name><surname>Shin</surname> <given-names>J.-H.</given-names></name> <name><surname>Han</surname> <given-names>C. E.</given-names></name> <name><surname>Kim</surname> <given-names>H. J.</given-names></name> <name><surname>Na</surname> <given-names>D. L.</given-names></name> <name><surname>Seo</surname> <given-names>S. W.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Using individualized brain network for analyzing structural covariance of the cerebral cortex in Alzheimer&#x02019;s patients</article-title>. <source>Front. Neurosci.</source> <volume>10</volume>:<fpage>394</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00394</pub-id><pub-id pub-id-type="pmid">27635121</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landau</surname> <given-names>S. M.</given-names></name> <name><surname>Thomas</surname> <given-names>B. A.</given-names></name> <name><surname>Thurfjell</surname> <given-names>L.</given-names></name> <name><surname>Schmidt</surname> <given-names>M.</given-names></name> <name><surname>Margolin</surname> <given-names>R.</given-names></name> <name><surname>Mintun</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Amyloid PET imaging in Alzheimer&#x02019;s disease: a comparison of three radiotracers</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source> <volume>41</volume>, <fpage>1398</fpage>&#x02013;<lpage>1407</lpage>. <pub-id pub-id-type="doi">10.1007/s00259-014-2753-3</pub-id><pub-id pub-id-type="pmid">24647577</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lerch</surname> <given-names>J. P.</given-names></name> <name><surname>Worsley</surname> <given-names>K.</given-names></name> <name><surname>Shaw</surname> <given-names>W. P.</given-names></name> <name><surname>Greenstein</surname> <given-names>D. K.</given-names></name> <name><surname>Lenroot</surname> <given-names>R. K.</given-names></name> <name><surname>Giedd</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Mapping anatomical correlations across cerebral cortex (MACACC) using cortical thickness from MRI</article-title>. <source>Neuroimage</source> <volume>31</volume>, <fpage>993</fpage>&#x02013;<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.042</pub-id><pub-id pub-id-type="pmid">16624590</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maslov</surname> <given-names>S.</given-names></name> <name><surname>Sneppen</surname> <given-names>K.</given-names></name></person-group> (<year>2002</year>). <article-title>Specificity and stability in topology of protein networks</article-title>. <source>Science</source> <volume>296</volume>, <fpage>910</fpage>&#x02013;<lpage>913</lpage>. <pub-id pub-id-type="doi">10.1126/science.1065103</pub-id><pub-id pub-id-type="pmid">11988575</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathis</surname> <given-names>C. A.</given-names></name> <name><surname>Mason</surname> <given-names>N. S.</given-names></name> <name><surname>Lopresti</surname> <given-names>B. J.</given-names></name> <name><surname>Klunk</surname> <given-names>W. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Development of positron emission tomography &#x003B2;-amyloid plaque imaging agents</article-title>. <source>Semin. Nucl. Med.</source> <volume>42</volume>, <fpage>423</fpage>&#x02013;<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1053/j.semnuclmed.2012.07.001</pub-id><pub-id pub-id-type="pmid">23026364</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattsson</surname> <given-names>N.</given-names></name> <name><surname>Insel</surname> <given-names>P. S.</given-names></name> <name><surname>Donohue</surname> <given-names>M.</given-names></name> <name><surname>Landau</surname> <given-names>S.</given-names></name> <name><surname>Jagust</surname> <given-names>W. J.</given-names></name> <name><surname>Shaw</surname> <given-names>L. M.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Independent information from cerebrospinal fluid amyloid-&#x003B2; and florbetapir imaging in Alzheimer&#x02019;s disease</article-title>. <source>Brain</source> <volume>138</volume>, <fpage>772</fpage>&#x02013;<lpage>783</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awu367</pub-id><pub-id pub-id-type="pmid">25541191</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname> <given-names>W. S.</given-names></name></person-group> (<year>2009</year>). <article-title>How does multiple testing correction work?</article-title> <source>Nat. Biotechnol.</source> <volume>27</volume>, <fpage>1135</fpage>&#x02013;<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1209-1135</pub-id><pub-id pub-id-type="pmid">20010596</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname> <given-names>H.</given-names></name> <name><surname>Habeck</surname> <given-names>C.</given-names></name> <name><surname>Madison</surname> <given-names>C.</given-names></name> <name><surname>Jagust</surname> <given-names>W.</given-names></name></person-group> (<year>2014</year>). <article-title>Covarying alterations in A&#x003B2; deposition, glucose metabolism, and gray matter volume in cognitively normal elderly</article-title>. <source>Hum. Brain Mapp.</source> <volume>35</volume>, <fpage>297</fpage>&#x02013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.22173</pub-id><pub-id pub-id-type="pmid">22965806</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname> <given-names>H.</given-names></name> <name><surname>Mormino</surname> <given-names>E. C.</given-names></name> <name><surname>Madison</surname> <given-names>C.</given-names></name> <name><surname>Hayenga</surname> <given-names>A.</given-names></name> <name><surname>Smiljic</surname> <given-names>A.</given-names></name> <name><surname>Jagust</surname> <given-names>W. J.</given-names></name></person-group> (<year>2011</year>). <article-title>&#x003B2;-Amyloid affects frontal and posterior brain networks in normal aging</article-title>. <source>Neuroimage</source> <volume>54</volume>, <fpage>1887</fpage>&#x02013;<lpage>1895</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.10.027</pub-id><pub-id pub-id-type="pmid">20965254</pub-id></citation></ref>
<ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ossenkoppele</surname> <given-names>R.</given-names></name> <name><surname>Schonhaut</surname> <given-names>D. R.</given-names></name> <name><surname>Sch&#x000F6;ll</surname> <given-names>M.</given-names></name> <name><surname>Lockhart</surname> <given-names>S. N.</given-names></name> <name><surname>Ayakta</surname> <given-names>N.</given-names></name> <name><surname>Baker</surname> <given-names>S. L.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x02019;s disease</article-title>. <source>Brain</source> <volume>139</volume>, <fpage>1551</fpage>&#x02013;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1093/brain/aww027</pub-id><pub-id pub-id-type="pmid">26962052</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmqvist</surname> <given-names>S.</given-names></name> <name><surname>Mattsson</surname> <given-names>N.</given-names></name> <name><surname>Hansson</surname> <given-names>O.</given-names></name> <collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab></person-group> (<year>2016</year>). <article-title>Cerebrospinal fluid analysis detects cerebral amyloid-&#x003B2; accumulation earlier than positron emission tomography</article-title>. <source>Brain</source> <volume>139</volume>, <fpage>1226</fpage>&#x02013;<lpage>1236</lpage>. <pub-id pub-id-type="doi">10.1093/brain/aww015</pub-id><pub-id pub-id-type="pmid">26936941</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname> <given-names>J. B.</given-names></name> <name><surname>Mijalkov</surname> <given-names>M.</given-names></name> <name><surname>Kakaei</surname> <given-names>E.</given-names></name> <name><surname>Mecocci</surname> <given-names>P.</given-names></name> <name><surname>Vellas</surname> <given-names>B.</given-names></name> <name><surname>Tsolaki</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Disrupted network topology in patients with stable and progressive mild cognitive impairment and Alzheimer&#x02019;s disease</article-title>. <source>Cereb. Cortex</source> <volume>26</volume>, <fpage>3476</fpage>&#x02013;<lpage>3493</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhw128</pub-id><pub-id pub-id-type="pmid">27178195</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prescott</surname> <given-names>J. W.</given-names></name> <name><surname>Guidon</surname> <given-names>A.</given-names></name> <name><surname>Doraiswamy</surname> <given-names>P. M.</given-names></name> <name><surname>Roy Choudhury</surname> <given-names>K.</given-names></name> <name><surname>Liu</surname> <given-names>C.</given-names></name> <name><surname>Petrella</surname> <given-names>J. R.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden</article-title>. <source>Radiology</source> <volume>273</volume>, <fpage>175</fpage>&#x02013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.14132593</pub-id><pub-id pub-id-type="pmid">24865310</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinov</surname> <given-names>M.</given-names></name> <name><surname>Sporns</surname> <given-names>O.</given-names></name></person-group> (<year>2010</year>). <article-title>Complex network measures of brain connectivity: uses and interpretations</article-title>. <source>Neuroimage</source> <volume>52</volume>, <fpage>1059</fpage>&#x02013;<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.10.003</pub-id><pub-id pub-id-type="pmid">19819337</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smit</surname> <given-names>D. J. A.</given-names></name> <name><surname>Boersma</surname> <given-names>M.</given-names></name> <name><surname>Schnack</surname> <given-names>H. G.</given-names></name> <name><surname>Micheloyannis</surname> <given-names>S.</given-names></name> <name><surname>Boomsma</surname> <given-names>D. I.</given-names></name> <name><surname>Hulshoff Pol</surname> <given-names>H. E.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>The brain matures with stronger functional connectivity and decreased randomness of its network</article-title>. <source>PLoS One</source> <volume>7</volume>:<fpage>e36896</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0036896</pub-id><pub-id pub-id-type="pmid">22615837</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sporns</surname> <given-names>O.</given-names></name> <name><surname>Chialvo</surname> <given-names>D. R.</given-names></name> <name><surname>Kaiser</surname> <given-names>M.</given-names></name> <name><surname>Hilgetag</surname> <given-names>C. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Organization, development and function of complex brain networks</article-title>. <source>Trends Cogn. Sci.</source> <volume>8</volume>, <fpage>418</fpage>&#x02013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1016/j.tics.2004.07.008</pub-id><pub-id pub-id-type="pmid">15350243</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teipel</surname> <given-names>S. J.</given-names></name> <name><surname>Cavedo</surname> <given-names>E.</given-names></name> <name><surname>Weschke</surname> <given-names>S.</given-names></name> <name><surname>Grothe</surname> <given-names>M. J.</given-names></name> <name><surname>Rojkova</surname> <given-names>K.</given-names></name> <name><surname>Fontaine</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints</article-title>. <source>Neurobiol. Aging</source> <volume>57</volume>, <fpage>143</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.05.016</pub-id><pub-id pub-id-type="pmid">28646687</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>B. A.</given-names></name> <name><surname>Erlandsson</surname> <given-names>K.</given-names></name> <name><surname>Modat</surname> <given-names>M.</given-names></name> <name><surname>Thurfjell</surname> <given-names>L.</given-names></name> <name><surname>Vandenberghe</surname> <given-names>R.</given-names></name> <name><surname>Ourselin</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>The importance of appropriate partial volume correction for PET quantification in Alzheimer&#x02019;s disease</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source> <volume>38</volume>, <fpage>1104</fpage>&#x02013;<lpage>1119</lpage>. <pub-id pub-id-type="doi">10.1007/s00259-011-1745-9</pub-id><pub-id pub-id-type="pmid">21336694</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tijms</surname> <given-names>B. M.</given-names></name> <name><surname>M&#x000F6;ller</surname> <given-names>C.</given-names></name> <name><surname>Vrenken</surname> <given-names>H.</given-names></name> <name><surname>Wink</surname> <given-names>A. M.</given-names></name> <name><surname>de Haan</surname> <given-names>W.</given-names></name> <name><surname>van der Flier</surname> <given-names>W. M.</given-names></name> <etal/></person-group>. (<year>2013a</year>). <article-title>Single-subject grey matter graphs in Alzheimer&#x02019;s disease</article-title>. <source>PLoS One</source> <volume>8</volume>:<fpage>e58921</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0058921</pub-id><pub-id pub-id-type="pmid">23536835</pub-id></citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tijms</surname> <given-names>B. M.</given-names></name> <name><surname>Wink</surname> <given-names>A. M.</given-names></name> <name><surname>de Haan</surname> <given-names>W.</given-names></name> <name><surname>van der Flier</surname> <given-names>W. M.</given-names></name> <name><surname>Stam</surname> <given-names>C. J.</given-names></name> <name><surname>Scheltens</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2013b</year>). <article-title>Alzheimer&#x02019;s disease: connecting findings from graph theoretical studies of brain networks</article-title>. <source>Neurobiol. Aging</source> <volume>34</volume>, <fpage>2023</fpage>&#x02013;<lpage>2036</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.02.020</pub-id><pub-id pub-id-type="pmid">23541878</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tijms</surname> <given-names>B. M.</given-names></name> <name><surname>Seri&#x000E8;s</surname> <given-names>P.</given-names></name> <name><surname>Willshaw</surname> <given-names>D. J.</given-names></name> <name><surname>Lawrie</surname> <given-names>S. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Similarity-based extraction of individual networks from gray matter MRI scans</article-title>. <source>Cereb. Cortex</source> <volume>22</volume>, <fpage>1530</fpage>&#x02013;<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhr221</pub-id><pub-id pub-id-type="pmid">21878484</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tijms</surname> <given-names>B. M.</given-names></name> <name><surname>Ten Kate</surname> <given-names>M.</given-names></name> <name><surname>Gouw</surname> <given-names>A. A.</given-names></name> <name><surname>Borta</surname> <given-names>A.</given-names></name> <name><surname>Verfaillie</surname> <given-names>S.</given-names></name> <name><surname>Teunissen</surname> <given-names>C. E.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Gray matter networks and clinical progression in subjects with predementia Alzheimer&#x02019;s disease</article-title>. <source>Neurobiol. Aging</source> <volume>61</volume>, <fpage>75</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.09.011</pub-id><pub-id pub-id-type="pmid">29040871</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tijms</surname> <given-names>B. M.</given-names></name> <name><surname>ten Kate</surname> <given-names>M.</given-names></name> <name><surname>Wink</surname> <given-names>A. M.</given-names></name> <name><surname>Visser</surname> <given-names>P. J.</given-names></name> <name><surname>Ecay</surname> <given-names>M.</given-names></name> <name><surname>Clerigue</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Gray matter network disruptions and amyloid beta in cognitively normal adults</article-title>. <source>Neurobiol. Aging</source> <volume>37</volume>, <fpage>154</fpage>&#x02013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.10.015</pub-id><pub-id pub-id-type="pmid">26559882</pub-id></citation></ref>
<ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tijms</surname> <given-names>B. M.</given-names></name> <name><surname>Yeung</surname> <given-names>H. M.</given-names></name> <name><surname>Sikkes</surname> <given-names>S. A. M.</given-names></name> <name><surname>M&#x000F6;ller</surname> <given-names>C.</given-names></name> <name><surname>Smits</surname> <given-names>L. L.</given-names></name> <name><surname>Stam</surname> <given-names>C. J.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Single-subject gray matter graph properties and their relationship with cognitive impairment in early- and late-onset Alzheimer&#x02019;s disease</article-title>. <source>Brain Connect.</source> <volume>4</volume>, <fpage>337</fpage>&#x02013;<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1089/brain.2013.0209</pub-id><pub-id pub-id-type="pmid">24735020</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trachtenberg</surname> <given-names>A. J.</given-names></name> <name><surname>Filippini</surname> <given-names>N.</given-names></name> <name><surname>Ebmeier</surname> <given-names>K. P.</given-names></name> <name><surname>Smith</surname> <given-names>S. M.</given-names></name> <name><surname>Karpe</surname> <given-names>F.</given-names></name> <name><surname>Mackay</surname> <given-names>C. E.</given-names></name></person-group> (<year>2012</year>). <article-title>The effects of APOE on the functional architecture of the resting brain</article-title>. <source>Neuroimage</source> <volume>59</volume>, <fpage>565</fpage>&#x02013;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.07.059</pub-id><pub-id pub-id-type="pmid">21851856</pub-id></citation></ref>
<ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tzourio-Mazoyer</surname> <given-names>N.</given-names></name> <name><surname>Landeau</surname> <given-names>B.</given-names></name> <name><surname>Papathanassiou</surname> <given-names>D.</given-names></name> <name><surname>Crivello</surname> <given-names>F.</given-names></name> <name><surname>Etard</surname> <given-names>O.</given-names></name> <name><surname>Delcroix</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain</article-title>. <source>Neuroimage</source> <volume>15</volume>, <fpage>273</fpage>&#x02013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1006/nimg.2001.0978</pub-id><pub-id pub-id-type="pmid">11771995</pub-id></citation></ref>
<ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Berckel</surname> <given-names>B. N. M.</given-names></name> <name><surname>Ossenkoppele</surname> <given-names>R.</given-names></name> <name><surname>Tolboom</surname> <given-names>N.</given-names></name> <name><surname>Yaqub</surname> <given-names>M.</given-names></name> <name><surname>Foster-Dingley</surname> <given-names>J. C.</given-names></name> <name><surname>Windhorst</surname> <given-names>A. D.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Longitudinal amyloid imaging using 11C-PiB: methodologic considerations</article-title>. <source>J. Nucl. Med.</source> <volume>54</volume>, <fpage>1570</fpage>&#x02013;<lpage>1576</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.112.113654</pub-id><pub-id pub-id-type="pmid">23940304</pub-id></citation></ref>
<ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>V&#x000E1;&#x00161;a</surname> <given-names>F.</given-names></name> <name><surname>Seidlitz</surname> <given-names>J.</given-names></name> <name><surname>Romero-Garcia</surname> <given-names>R.</given-names></name> <name><surname>Whitaker</surname> <given-names>K. J.</given-names></name> <name><surname>Rosenthal</surname> <given-names>G.</given-names></name> <name><surname>V&#x000E9;rtes</surname> <given-names>P. E.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Adolescent tuning of association cortex in human structural brain networks</article-title>. <source>Cereb. Cortex</source> <volume>28</volume>, <fpage>281</fpage>&#x02013;<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhx249</pub-id><pub-id pub-id-type="pmid">29088339</pub-id></citation></ref>
<ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villain</surname> <given-names>N.</given-names></name> <name><surname>Ch&#x000E9;telat</surname> <given-names>G.</given-names></name> <name><surname>Grassiot</surname> <given-names>B.</given-names></name> <name><surname>Bourgeat</surname> <given-names>P.</given-names></name> <name><surname>Jones</surname> <given-names>G.</given-names></name> <name><surname>Ellis</surname> <given-names>K. A.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Regional dynamics of amyloid-&#x003B2; deposition in healthy elderly, mild cognitive impairment and Alzheimer&#x02019;s disease: a voxelwise PiB-PET longitudinal study</article-title>. <source>Brain</source> <volume>135</volume>, <fpage>2126</fpage>&#x02013;<lpage>2139</lpage>. <pub-id pub-id-type="doi">10.1093/brain/aws125</pub-id><pub-id pub-id-type="pmid">22628162</pub-id></citation></ref>
<ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villemagne</surname> <given-names>V. L.</given-names></name> <name><surname>Burnham</surname> <given-names>S.</given-names></name> <name><surname>Bourgeat</surname> <given-names>P.</given-names></name> <name><surname>Brown</surname> <given-names>B.</given-names></name> <name><surname>Ellis</surname> <given-names>K. A.</given-names></name> <name><surname>Salvado</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Amyloid &#x003B2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x02019;s disease: a prospective cohort study</article-title>. <source>Lancet Neurol.</source> <volume>12</volume>, <fpage>357</fpage>&#x02013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(13)70044-9</pub-id><pub-id pub-id-type="pmid">23477989</pub-id></citation></ref>
<ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villemagne</surname> <given-names>V. L.</given-names></name> <name><surname>Fodero-Tavoletti</surname> <given-names>M. T.</given-names></name> <name><surname>Masters</surname> <given-names>C. L.</given-names></name> <name><surname>Rowe</surname> <given-names>C. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Tau imaging: early progress and future directions</article-title>. <source>Lancet Neurol.</source> <volume>14</volume>, <fpage>114</fpage>&#x02013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(14)70252-2</pub-id><pub-id pub-id-type="pmid">25496902</pub-id></citation></ref>
<ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villeneuve</surname> <given-names>S.</given-names></name> <name><surname>Rabinovici</surname> <given-names>G. D.</given-names></name> <name><surname>Cohn-Sheehy</surname> <given-names>B. I.</given-names></name> <name><surname>Madison</surname> <given-names>C.</given-names></name> <name><surname>Ayakta</surname> <given-names>N.</given-names></name> <name><surname>Ghosh</surname> <given-names>P. M.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation</article-title>. <source>Brain</source> <volume>138</volume>, <fpage>2020</fpage>&#x02013;<lpage>2033</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awv112</pub-id><pub-id pub-id-type="pmid">25953778</pub-id></citation></ref>
<ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname> <given-names>D. J.</given-names></name> <name><surname>Strogatz</surname> <given-names>S. H.</given-names></name></person-group> (<year>1998</year>). <article-title>Collective dynamics of &#x02018;small-world&#x02019; networks</article-title>. <source>Nature</source> <volume>393</volume>, <fpage>440</fpage>&#x02013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1038/30918</pub-id><pub-id pub-id-type="pmid">9623998</pub-id></citation></ref>
<ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>C.</given-names></name> <name><surname>Makaretz</surname> <given-names>S. J.</given-names></name> <name><surname>Caso</surname> <given-names>C.</given-names></name> <name><surname>McGinnis</surname> <given-names>S.</given-names></name> <name><surname>Gomperts</surname> <given-names>S. N.</given-names></name> <name><surname>Sepulcre</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Association of <italic>in vivo</italic> [<sup>18</sup>F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease</article-title>. <source>JAMA Neurol.</source> <volume>74</volume>, <fpage>427</fpage>&#x02013;<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2016.5755</pub-id><pub-id pub-id-type="pmid">28241163</pub-id></citation></ref>
<ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>M.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>BrainNet Viewer: a network visualization tool for human brain connectomics</article-title>. <source>PLoS One</source> <volume>8</volume>:<fpage>e68910</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0068910</pub-id><pub-id pub-id-type="pmid">23861951</pub-id></citation></ref>
<ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>T.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Mapping the Alzheimer&#x02019;s brain with connectomics</article-title>. <source>Front. Psychiatry</source> <volume>2</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2011.00077</pub-id><pub-id pub-id-type="pmid">22291664</pub-id></citation></ref>
<ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>Z.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Lin</surname> <given-names>L.</given-names></name> <name><surname>Zhou</surname> <given-names>Y.</given-names></name> <name><surname>Xu</surname> <given-names>C.</given-names></name> <name><surname>Jiang</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Abnormal cortical networks in mild cognitive impairment and Alzheimer&#x02019;s disease</article-title>. <source>PLoS Comput. Biol.</source> <volume>6</volume>:<fpage>e1001006</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1001006</pub-id><pub-id pub-id-type="pmid">21124954</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="fn0001"><p><sup>1</sup><ext-link ext-link-type="uri" xlink:href="http://cati-neuroimaging.com">cati-neuroimaging.com</ext-link></p></fn>
<fn id="fn0002"><p><sup>2</sup><ext-link ext-link-type="uri" xlink:href="https://github.com/bettytijms/Single_Subject_Grey_Matter_Networks">https://github.com/bettytijms/Single_Subject_Grey_Matter_Networks</ext-link></p></fn>
<fn id="fn0003"><p><sup>3</sup><ext-link ext-link-type="uri" xlink:href="http://www.brain-connectivity-toolbox.net">www.brain-connectivity-toolbox.net</ext-link></p></fn>
<fn id="fn0004"><p><sup>4</sup><ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link></p></fn>
</fn-group>
</back>
</article>